← Back to Clinical Trials
Recruiting NCT07735156

NCT07735156 Endovascular Management of Pelvic Congestion Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07735156
Status Recruiting
Phase
Sponsor Sohag University
Condition Pelvic Congestion Syndrome
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-01-14
Primary Completion 2027-01-01

Eligibility & Interventions

Sex Female only
Min Age 17 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Endovascular embolization

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-01-14 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Pelvic congestion syndrome (PCS) is a common cause of chronic pelvic pain in women and is associated with pelvic venous insufficiency. This prospective interventional study aims to evaluate the safety and clinical effectiveness of endovascular embolization in relieving symptoms and improving quality of life in women diagnosed with PCS

Eligibility Criteria

Inclusion Criteria: * Female patients aged 18 years or older. * Chronic pelvic pain for more than 6 months. * Clinical suspicion of pelvic congestion syndrome. * Imaging findings consistent with pelvic congestion syndrome on Doppler ultrasound, CT venography, MR venography, or catheter venography. * Patients willing to undergo endovascular embolization. * Written informed consent obtained Exclusion Criteria: * Pregnancy. * Active pelvic inflammatory disease. * Known pelvic malignancy. * Chronic pelvic pain due to other identifiable causes (e.g., endometriosis, large uterine fibroids). * Contraindication to iodinated contrast media. * Severe renal impairment. * Uncorrectable coagulation disorders. * Refusal to participate.

Contact & Investigator

Central Contact

Ahmed Nageh Younis, M.B.B.Ch.

✉ Ahmed.Nageh@med.sohag.edu.eg

📞 00201009800845

Principal Investigator

Mohammed Zaki Ali, Professor of Radiology

PRINCIPAL INVESTIGATOR

Sohag University

Frequently Asked Questions

Who can join the NCT07735156 clinical trial?

This trial is open to female participants only, aged 17 Years or older, up to 55 Years, studying Pelvic Congestion Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07735156 currently recruiting?

Yes, NCT07735156 is actively recruiting participants. Contact the research team at Ahmed.Nageh@med.sohag.edu.eg for enrollment information.

Where is the NCT07735156 trial being conducted?

This trial is being conducted at Sohag, Egypt.

Who is sponsoring the NCT07735156 clinical trial?

NCT07735156 is sponsored by Sohag University. The principal investigator is Mohammed Zaki Ali, Professor of Radiology at Sohag University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology